Abstract
Transcutaneous immunization, a topical vaccine application, combines the advantages of needle-free delivery while targeting the immunologically rich milieu of the skin. In animal studies, this simple technique induces robust systemic and mucosal antibodies against vaccine antigens. Here, we demonstrate safe application of a patch containing heat-labile enterotoxin (LT, derived from Escherichia coli) to humans, resulting in robust LT-antibody responses. These findings indicate that TCI is feasible for human immunization, and suggest that TCI may enhance efficacy as well as improve vaccine delivery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).
Snider, D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15, 317–348 (1995).
Michetti, P. et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116, 804–812 (1999).
Gluck, R. et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181, 1129–1132 (2000).
Glenn, G.M., Scharton-Kersten, T., Vassell, R., Matyas, G. & Alving. C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67, 1100–1106 (1999).
Reducing the risk of unsafe injections in immunization programmes: The role of injection equipment. World Health Organization Expanded Programme on Immunization. (WHO, Geneva, Switzerland, 1996).
Yu, R., Abrams, D., Alaibac, M. & Chu, A. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Brit. J. Dermatol. 131, 843–848 (1994).
Barry, B.W. Dermatologic formulations. in: Percutaneous Absorption: Methods, Methodology, Drug Delivery. (eds. Bronaugh, R.L. & Maibach, H.I.) 33 (Marcel Dekker, New York, 1985).
Kripke, M.L., Dunn, C.G., Jeevan, A., Tang, J. & Bucana, C. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145, 2833–2838 (1990).
Holmgren, J. et al. Antitoxic immunity in experimental cholera: Protection and serum and local antibody responses in rabbits after enteric and parenteral immunization. Infect. Immun. 12, 1331–1340 (1975).
Clemens, J.D. et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial. J. Infect. Dis. 158, 372–377 (1988).
Aiba, S. & Katz, S. Phenotypic and functional characteristics of in vivo activated Langerhans cells. J. Immunol. 145, 2791–2796 (1990).
Noble, B., Gorfien, J., Frankel, S., Rossman, J. & Brodsky, L. Microanatomical distribution of dendritic cells in normal tonsils. Acta. Otolaryngol. Suppl. (Stockh) 523, S94–S97 (1996).
Glenn, G.M. et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161, 3211–3214 (1998).
Glenn, G.M., Scharton-Kersten, T. & Alving, C.R. Advances in vaccine delivery: transcutaneous immunisation. Exp. Opin. Invest. Drugs 8, 797–805 (1999).
Seo, N. et al. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad Sci. USA 97, 371–376 (2000).
Wang, L., Lin J., Hsieh, K. & Lin R. Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice. J. Immunol. 156, 4077–4082 (1996).
Bouvet, J. & Fischetti, V. Diversity of antibody-mediated immunity at the mucosal barrier. Infect. Immun. 67, 2687–2691 (1999).
Roberts, M.S. & Walker, M. Water, the most natural penetration enhancer. in: Pharmaceutical Skin Penetration Enhancement (eds. Walters, K.A. & Hadgraft, J.) 1–30 (Marcel Dekker, New York, 1993).
Cope, R.B. & Colditz, I.G. Effect on systemic antibody concentrations of topical application of cholera toxin to skin of sheep. Aust. Vet. J. 78, 121–123 (2000).
Udey, M.C. Cadherins and Langerhans cells immunobiology. Clin. Exp. Immunol. 107 (Suppl. 1), 6–8 (1997).
Bouloc, A., Walker, P., Grivel, J., Vogel J. & Katz, S. Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells. Eur. J. Immunol. 29, 446–454 (1999).
Scharton-Kersten, T. et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68, 5306–5313 (2000).
Svennerholm, A-M., Holmgren, J., Black, R., Levine, M. & Merson, M. Serologic differentation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J. Infect. Dis. 147, 514–522 (1983).
Rudin, A., Riise, G. & Holmgren, J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect. Immun. 67, 2884–2890 (1999).
Acknowledgements
The authors wish to thank D. McKinney for clinical support and the Medical Technologies and Practice Patterns Institute for administrative support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Glenn, G., Taylor, D., Li, X. et al. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat Med 6, 1403–1406 (2000). https://doi.org/10.1038/82225
Issue Date:
DOI: https://doi.org/10.1038/82225
This article is cited by
-
The role of engineered materials in mucosal vaccination strategies
Nature Reviews Materials (2023)
-
Transdermal Delivery Systems for Biomolecules
Journal of Pharmaceutical Innovation (2022)
-
Novel Allergen Immunotherapy Routes
Current Treatment Options in Allergy (2016)
-
Allergenspezifische Immuntherapie bei Rhinitis allergica
HNO (2015)
-
DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response
Molecular Therapy - Methods & Clinical Development (2014)